autoimmune disease treatments
Scope
Date
~
-
Bio & Pharma
Celltrion applies for Phase 3 clinical trials in Europe for biosimilar
South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...
May 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong to transfer techs for autoimmune disease to US pharma
South Korea's Daewoong Pharmaceutical announced on Friday that it has signed a technology export contract for the clinical development and commercia...
Apr 28, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's Kainos Medicine exports AIDS treatment technology to China
South Korean new drug developer Kainos Medicine Inc. announced on Friday that it had signed a technology transfer agreement with Chinese pharmaceuti...
Apr 21, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare enters top 10 in hospital prescriptions in Turkey
South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turki...
Apr 21, 2023 (Gmt+09:00)
-
Korean startups
Asleep dreams big to help sleepless people worldwide find right treatment
Armed with artificial intelligence and big data technologies, Asleep hopes to find the best treatment for sleep-deprived people around the world wit...
Apr 21, 2023 (Gmt+09:00)
-
Bio & Pharma
AbClon shows promising results in clinical tests of leukemia treatment
South Korean companies are standing out in the global competition to develop chimeric antigen receptor T-cell (CAR-T) treatments, dubbed "dream" a...
Apr 19, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma, UK firm to jointly develop autoimmune disease drug
South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday that it has signed a cooperation agreement with Sygnature Discovery, a British ne...
Apr 18, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB starts Phase 3 clinical trials for ophthalmic disease treatment in US
South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has started patient administration of "RGN-259," a treatment...
Apr 13, 2023 (Gmt+09:00)
-
Bio & Pharma
JW Pharma receives 1st overseas patent for its hair loss treatment
JW Pharmaceutical, a drug company based in South Korea, has received its first patent for a hair loss treatment that is currently in development. Th...
Mar 27, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's microneedle maker Raphas to enter US market
South Korea's microneedle maker Raphas Co. is expediting its entry into the American pharmaceutical market after entering the country's cosmetics se...
Mar 27, 2023 (Gmt+09:00)
-
Bio & Pharma
PharmaResearch pays employees $7,706 bonus for having 3rd child
With South Korea setting new lows in birth rate every year, PharmaResearch on Wednesday said it will adopt an unprecedented system of childbirth and...
Mar 23, 2023 (Gmt+09:00)
-
Waste management
Toray Advanced Materials acquires S.Korea's water treatment company
Toray Advanced Materials Korea Inc. announced on Monday the acquisition of Hanmee Entec Co., Ltd., the industry's longest-running water treatment fa...
Mar 20, 2023 (Gmt+09:00)
-
Bio & Pharma
Prestige Bio's pancreatic cancer treatment gets US FDA fast-track designation
Prestige Biopharma, a biopharmaceutical company in South Korea, announced on Thursday that their pancreatic cancer antibody drug, PBP1510 (Ulenistam...
Mar 16, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong wins approval for GERD treatment Fexuclu in Chile
South Korean pharmaceutical company Daewoong Pharmaceutical announced on Tuesday that it has received marketing authorization from Chile's National ...
Mar 14, 2023 (Gmt+09:00)
-
Bio & Pharma
OliX's hair loss treatment candidate approved for clinical trial in Australia
South Korea's OliX Pharmaceuticals has received approval from Australia's Human Research Ethics Committees (HREC) to plan a phase 1 clinical trial o...
Mar 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis launches ARMD biosimilar drug in Germany, Canada
Samsung Bioepis Co., a South Korean biosimilar firm, announced on Sunday that it has recently launched a new biosimilar drug called SB11 for the tre...
Mar 06, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma introduces candidates for treating blood coagulation disease
South Korea's GC Biopharma Corp. announced on Tuesday that it had entered into an agreement to transfer assets with Catalyst Biosciences, a US-based...
Mar 02, 2023 (Gmt+09:00)
-
Bio & Pharma
AIMMED’s Somzz ushers in digital therapeutic device market in Korea
South Korea’s health and drug safety authority has cleared Somzz to treat patients with sleep disorders, a dynamic move that is expected to vi...
Feb 16, 2023 (Gmt+09:00)
-
Healthcare
Daesang Wellife signs contract with RexSoft for healthcare platform
South Korea's Daesang Wellife Corp. has inked a 2 billion won ($1.5 million) investment contract with local healthcare data science company RexSoft ...
Feb 15, 2023 (Gmt+09:00)
-
Bio & Pharma
Vaxcell-Bio, Cellid sign MOU to build cancer immunotherapy platform
Vaxcell-Bio Therapeutics, a South Korean company specializing in anti-cancer immunotherapy, announced on Wednesday its partnership with Cellid Co. t...
Feb 15, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N's GERD drug K-CAB gets approval in Mexico
South Korea's biohealth company HK inno.N said on Tuesday that its gastroesophageal reflux disease (GERD) treatment K-CAB (active ingredient: tegopr...
Feb 14, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Plasma, Janssen Korea sign sales, distribution agreement
SK Plasma Co. Ltd., a South Korean company specializing in the production of plasma derivatives from human plasma, is expanding its product portfoli...
Feb 14, 2023 (Gmt+09:00)
-
Bio & Pharma
Hanall Biopharma invests in Interon Labs for brain disease treatments
South Korean pharmaceuticals firm Hanall Biopharma Co. is investing in Interon Laboratories, a US biotech firm that finds and develops treatments fo...
Feb 13, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB’s Rivoceranib, Hengrui's Camrelizumab approved as combination therapy in China
South Korea's HLB Co. announced on Thursday that the combination therapy of its drug candidate rivoceranib and Jiangsu Hengrui Pharmaceuticals Co., ...
Feb 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Humasis participates Dubai MEDLAB Middle East 2023
South Korean medical devices maker, Humasis Co., is participating in the MEDLAB Middle East 2023 event taking place at the Dubai World Trade Center ...
Feb 08, 2023 (Gmt+09:00)
-
Bio & Pharma
Hanmi's Rolvedon set to post $10 mn in Q4 net sales in US
South Korean drugmaker Hanmi Pharmaceutical Co.’s neutropenia agent, Rolvedon (eflapegrastim-xnst), is forecast to achieve about $10 million i...
Feb 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Bridge Biotherapeutics, Pinotbio develop lung cancer treatment
South Korea's biotech companies Bridge Biotherapeutics Inc. and Pinotbio on Thursday said they will jointly develop new antibody-drug conjugates (AD...
Jan 27, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N to introduce biosimilars for bone disease treatment from Spain
South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to intr...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Inventage Lab launches clinical trials for addiction treatment in Australia
South Korea's Inventage Lab, a developer of a drug delivery system platform, on Wednesday said it received approval from the Human Research Ethics C...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
ST Pharm exports $14.6 mn worth of drug ingredients to Europe
ST Pharm Co., a South Korean company specializing in contract development and manufacturing of drug ingredients, has signed a supply contract worth ...
Jan 20, 2023 (Gmt+09:00)